Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1519425
Reference Type
Journal Article
Subtype
Review
Title
Targeting the small airways asthma phenotype: if we can reach it, should we treat it?
Author(s)
Lipworth, B
Year
2013
Is Peer Reviewed?
Yes
Journal
Annals of Allergy, Asthma & Immunology
ISSN:
1081-1206
EISSN:
1534-4436
Volume
110
Issue
4
Page Numbers
233-239
Language
English
PMID
23535085
DOI
10.1016/j.anai.2013.02.009
Web of Science Id
WOS:000317274000005
Abstract
OBJECTIVE:
To review the available methods of evaluating the small airways disease in asthma and the therapeutic strategies to achieve better control using emerging extrafine particle inhaler technologies.
DATA SOURCES:
The PubMed, MEDLINE (Ebsco), Scirus, Scopus, and Google Scholar databases were all scanned with Cross-search using the following keywords: asthma, small airways, hydrofluoroalkane 134a, extrafine particle, inhaled corticosteroid, long-acting β-agonist, spirometry, impulse oscillometry, nitrogen washout, exhaled nitric oxide, airway hyperresponsiveness, and adrenal suppression.
STUDY SELECTION:
Key clinical studies considered to being relevant to the topic under review were evaluated.
RESULTS:
There is an unmet need in current asthma guidelines for those individuals who exhibit the small airways asthma phenotype with a preserved forced expiratory volume in 1 second but abnormal forced midexpiratory flow and peripheral airway resistance, which tends to be associated with poorer control. Extrafine hydrofluoroalkane solution formulations of inhaled corticosteroid either alone or in combination with long-acting β-agonist may improve small airways outcomes and associated control.
CONCLUSION:
From a pragmatic perspective, it makes sense to try to deliver asthma treatment to more of the lung to improve clinical outcomes, especially in patients who exhibit the small airways asthma phenotype.
Keywords
Adrenal Cortex Hormones/administration & dosage/therapeutic use; Adrenergic beta-Agonists/administration & dosage/therapeutic use; Airway Resistance; Anti-Asthmatic Agents/administration & dosage/therapeutic use; Asthma/drug therapy/physiopathology; Clinical Trials as Topic; Drug Therapy, Combination; Hydrocarbons, Fluorinated/administration & dosage/therapeutic use; Nebulizers and Vaporizers; Phenotype; Respiratory Function Tests; Respiratory System/pathology/physiopathology
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity